Healthcare Professional Man in suit

Your Partnership Matters in Cancer Research

We are passionate about improving health and are committed to helping people with cancer. The purpose of the Keynote Oncology Clinical Trials is to determine whether the investigational immunotherapy, pembrolizumab (MK-3475), may help in the treatment of cancer. We have clinical trials planned in multiple cancer types.

Pembrolizumab is a PD-1 blocking antibody that may block the interaction between the programmed cell death-1 receptor (PD-1) and its ligands, PD-L1 and PD-L2. In some patients, blocking this pathway may enable the immune system to fight the cancer.

The FDA has approved pembrolizumab for use in certain patients with advanced melanoma, metastatic non-small cell lung cancer, and recurrent or metastatic head and neck squamous cell carcinoma.

There is a great deal more to understand and learn about which patients are likely to respond to immunotherapy. Ongoing research may help us understand this, as well as provide insights regarding how to best test for expression of biomarkers that may better direct clinical care.

To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.

50

Trials in 30+ cancer types

Explore Active Clinical Trials

  • expand all
  • |
  • collapse all
Trial Description Keynote Trial Condition Phase and Status Learn More
A Trial of Pembrolizumab in Participants With Blood Cancers 013
  • Myelodysplastic Syndrome
  • Multiple Myeloma
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Primary Mediastinal B-Cell Lymphoma
Phase 1Recruiting NCT01953692
A Study of Pembrolizumab in Combination With Standard of Care Treatments in Participants With Multiple Myeloma 023 Multiple Myeloma Phase 1Recruiting NCT02036502
Study of Pembrolizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma 087 Hodgkin Lymphoma Phase 2Active, not recruiting NCT02453594
Study of Pembrolizumab in Combination With Dinaciclib in Hematologic Malignancies 155
  • rrCLL
  • rrMM
  • rrDLBCL
Phase 1Recruiting NCT02684617
Study of Pembrolizumab in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome 170
  • Mediastinal Large B-cell Lymphoma
  • Richter Syndrome
Phase 2Recruiting NCT02576990
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab in Refractory or Relapsed and Refractory Multiple Myeloma 183 Multiple Myeloma Phase 3Recruiting NCT02576977
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma 185 Multiple Myeloma Phase 3Recruiting NCT02579863
Study of Pembrolizumab vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma 204 Hodgkin Lymphoma Phase 3Recruiting NCT02684292
Trial Description Keynote Trial Condition Phase and Status Learn More
Study of Two Doses of Pembrolizumab Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer 010 Non Small Cell Lung Cancer (NSCLC) Phase 2/Phase 3Active, not recruiting NCT01905657
Study of Pembrolizumab Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer 011
  • Solid Tumor
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
Phase 1Recruiting NCT01840579
A Study of Pembrolizumab in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer 021 Non-small Cell Lung Carcinoma Phase 1/Phase 2Active, not recruiting NCT02039674
Study of Pembrolizumab Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer 024 Non-Small Cell Lung Carcinoma Phase 3Active, not recruiting NCT02142738
Study of Pembrolizumab in Participants With Advanced Non-small Cell Lung Cancer 025 Non-small Cell Lung Cancer Phase 1Active, not recruiting NCT02007070
Study of MK-3475 Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer 042 Non-small Cell Lung Cancer Phase 3Active, not recruiting NCT02220894
Study of Pembrolizumab vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy 091 Non-small Cell Lung Cancer Phase 3Recruiting NCT02504372
Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer 189 Non-Small-Cell Lung Carcinoma Phase 3Active, not recruiting NCT02578680
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer 407 Non-small Cell Lung Cancer Phase 3Recruiting NCT02775435